Suprefort
Pancreatic peptide bioregulator
Suprefort (Pancreatic peptide bioregulator) is a longevity & bioregulators research compound. Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate metabolism.
Suprefort quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
Pancreatic cytogen — metabolic support, courses. Aimed at the pancreas — both the digestive-enzyme side and the insulin-producing side, which is why it turns up in metabolic protocols. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, fasting insulin, fasting glucose and HbA1c before and at 3 months. Run it as an experiment you measure, not a protocol you trust.
How Suprefort works
Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate metabolism.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Suprefort
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Suprefort
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- The pancreatic extract, sold for carbohydrate metabolism. Widely used within the bioregulator community for glucose goals, on no better footing than Pancragen.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A pancreas-derived peptide complex proposed to support pancreatic cell function.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- Anything claimed to affect glucose deserves a specific caution: if it did work, combining it with insulin or a sulfonylurea would carry real hypoglycemia risk, and nobody has characterized the interaction because nobody has characterized the effect.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Suprefort actually does
Suprefort is a pancreatic peptide complex, and the word ‘complex’ is doing more work than the word ‘pancreatic’. It is not a molecule. It is what remains after pancreatic tissue is extracted and size-fractionated, standardized by total peptide content rather than by composition. There is no sequence, so there is no formula, no exact mass, no isoelectric point and no computable charge at blood pH. Compare that with its own sibling on this site: Pancragen is Lys-Glu-Asp-Trp, C26H36N6O9, 576.61 Da, isoelectric point 4.18. Every one of those numbers can be checked against a vial. None of them exists here.
The delivery problem is worse for this product than for most, and the reason is anatomical. The pancreas sits behind the gut wall. A swallowed preparation aimed at it cannot work by contact the way a gastric or intestinal product could — it has to be absorbed, survive hepatic first-pass extraction, and arrive at pancreatic tissue through the circulation. The only named route across the intestinal epithelium in this school's own work is PEPT1, whose described substrate range is di- and tripeptides, 2 and 3 residues Khavinson 2022. A mixture of unstated chain lengths is not known to contain anything that short, and the 2023 docking assessment of 26 defined ultrashort peptides against those carriers says nothing about an undefined mixture Khavinson 2023. So the oral form has to clear a barrier its own mechanism cannot describe.
What the class proposes it does once inside. The argument is transcriptional: short peptides reaching chromatin and shifting tissue-specific gene expression Khavinson 2021. For the defined pancreatic tetrapeptide that argument has content — a named list of beta-cell transcription factors including PDX1, NGN3 and NKX6.1. For a complex there is no named target because there is no named molecule to have one. The mechanism is inherited, not demonstrated.
Cell, rodent, human — and where it stops
The count, and the method behind it. A search restricted to PubMed under the trade names of the oral organ-extract line on this site — Suprefort, Svetinorm, Vladonix, Chitomur — returns 1 indexed record between them, and it is a urology paper about bladder function in women. Nothing is indexed under this product's name on pancreatic function, in any species, in any language reachable that way. 0 trials, 0 animal studies, 0 mechanism papers.
The evidence people are actually leaning on is the tetrapeptide's. The best animal result in this tissue belongs to Pancragen, not to this product: old female rhesus monkeys, intramuscular microgram-scale dosing once daily for 10 days, a glucose challenge showing faster glucose disappearance and normalized insulin and C-peptide dynamics, with the effect partly persisting 3 weeks after the last dose Goncharova 2014. That is a primate study on a molecule with a sequence. This product is a mixture with no sequence and no study, sold for the same organ at a similar price.
The obstacles, and the first one is not fixable by more reading. (1) You cannot translate what you cannot define. A translation chain needs the same molecule at each step; with an unspecified mixture there is no way to know that 2 lots are even the same input. (2) The oral route requires absorption of something whose size distribution is unpublished. (3) There is no biodistribution work for any member of this family, so pancreatic delivery is assumed throughout. (4) The class's outside view is an independent systematic review of 24 randomized trials over 2,245 participants with risk of bias moderate to high, certainty of evidence low to very low, and no metabolic arm Alsulaimani 2021.
What would have to be true, and how you would know it was not
Three predictions. The first is the one nobody in this space gets right, and it invalidates most self-experiments on this product before they start.
1. HbA1c cannot answer the question, and fructosamine can. A course here is short. HbA1c reflects roughly the previous 2 to 3 months because it is written onto the lifespan of a red blood cell, and this site's own retest interval for it is every 3 months for exactly that reason. A 20 or 30-day course cannot move it interpretably. Fructosamine reflects roughly the previous 2 to 3 weeks, and this site retests it every 3 to 4 weeks during an active intervention. If this product does anything to glycemia on the schedule people actually run, fructosamine is the marker that can see it.
2. Fasting insulin needs a paired glucose or it will mislead. Insulin rising with glucose falling is improved secretion. Insulin rising with glucose flat is worsening resistance. Both read as ‘insulin went up’ on a single line of a report. This site retests fasting insulin 8 to 12 weeks after an intervention, so the draw belongs after the course rather than inside it, alongside the glucose on the same CMP.
3. The prediction that argues against this product specifically. If you want the pancreatic bioregulator with evidence behind it, the evidence is on the defined tetrapeptide and not on the extract Goncharova 2014. The falsifiable version: run both, 1 course each, separated by a washout, with fructosamine at baseline and 3 weeks after each course. The mechanistically honest expectation is that neither moves; the second expectation is that if either does, it is the one with the primate study. Nobody has ever compared them, which means the extract is priced as though the tetrapeptide's data were its own.
What nobody has tested yet
Four experiments, and 2 of them are cheaper than a course.
1. Nobody has published what is in a capsule. Liquid chromatography with tandem mass spectrometry on 1 lot would produce a peptide inventory: chain lengths, identifiable sequences, how much of anything is present. It is the measurement that would let this product be reasoned about at all, and 0 vendors publish it.
2. Nobody has measured what fraction survives the stomach. An in-vitro digestion assay — 1 hour at pH 1.5 to 3.5 with pepsin, then simulated intestinal fluid — is a standard food science protocol, and it would report the surviving fraction as a percentage. For an oral product whose target sits behind the gut wall, that number decides everything, and it has never been published for any preparation in this catalog.
3. Nobody has run the extract against the tetrapeptide. Same organ, same claim, 1 of them with a primate study. A single head-to-head with fructosamine and a stimulated C-peptide would tell a buyer which product to choose and would test whether extraction concentrates anything useful.
4. Nobody has tested the exocrine half. The pancreas has 2 jobs and this product is sold for both. Fecal elastase is the standard test of exocrine pancreatic function, it is a stool test rather than a blood draw, and it has never been measured before and after a course of anything in this family.
Suprefort — its own safety story, not its class's
Three things specific to a pancreatic extract taken by mouth.
The dangerous scenario is substitution in a person with real diabetes. Type 2 diabetes has treatments with randomized evidence and hard endpoints. This product has 0 human studies. Somebody postponing effective treatment while running courses of an uncharacterized capsule is accepting years of exposure to high glucose in exchange for a hypothesis, and the damage from that is cumulative and silent.
Autoimmune diabetes is the population in whom nothing here can work. In type 1 diabetes and latent autoimmune diabetes of adults the beta cells are being destroyed. C-peptide and insulin antibodies are the 2 ordinary tests that separate that group from type 2, and delay in that group is measured in days rather than months.
Animal-tissue provenance, which the synthetic peptides do not carry. An organ extract begins as an animal organ, which raises sourcing, viral inactivation and residual-protein questions that only a manufacturer can answer and that a sterility certificate does not address. No harm has been reported for this product — and with 0 human trials there has never been a setting in which it could have been. That zero is a statement about the evidence, not about the capsule.
Sources read for this page
- Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Advances in Gerontology 2014;27(4):662–667 · PMID 25946840
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Suprefort — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Suprefort — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Suprefort moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Suprefort in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Suprefort
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Suprefort — frequently asked questions
What is Suprefort?
Suprefort (Pancreatic peptide bioregulator) is a longevity & bioregulators research compound. Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate metabolism.
Is the full Suprefort protocol on this page?
The reported research dose is on this page, along with how Suprefort works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Suprefort?
Suprefort has an approximate half-life of ~15-30 min, which is part of what determines how often it's dosed.
What forms does Suprefort come in?
Suprefort is available as: Injectable, Oral.
What's the evidence behind Suprefort?
Current evidence level: Russian studies; limited. Suprefort is offered for research purposes only and is not an approved medicine.
Suprefort inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Suprefort is used for
Suprefort appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Suprefort is the endocrine & reproductive arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.